Vistaril Does Not Worsen Tardive Dyskinesia
Vistaril (hydroxyzine) does not make tardive dyskinesia worse and may actually provide therapeutic benefit. In fact, antihistaminic medications like hydroxyzine are used to treat acute dystonic reactions, which are related movement disorders 1.
Evidence Supporting Safety and Potential Benefit
Research Evidence
Two Japanese studies from the 1980s specifically examined hydroxyzine pamoate in patients with established tardive dyskinesia:
- Hydroxyzine reduced CSF HVA concentrations (a dopamine metabolite marker) in 2 of 4 patients who showed clinical improvement in their TD symptoms 2
- Hydroxyzine reduced CSF 5-HIAA concentrations (a serotonin metabolite) in all treated patients 3
- The reduction in dopamine metabolites suggests normalization of a hyperdopaminergic state, which is thought to contribute to TD pathophysiology 2
These findings indicate hydroxyzine may actually help TD rather than worsen it, though the evidence is limited to small case series.
Guideline Context
The American Academy of Child and Adolescent Psychiatry guidelines explicitly state that antihistaminic medications (which includes hydroxyzine) are used to treat acute dystonic reactions 1. While dystonia differs from tardive dyskinesia, this demonstrates that antihistamines do not exacerbate movement disorders caused by antipsychotics.
FDA Drug Label
The Vistaril FDA label does not list tardive dyskinesia as a side effect or contraindication 4. The label cautions about QT prolongation when used with certain antipsychotics, but makes no mention of worsening movement disorders.
Key Clinical Points
Hydroxyzine's mechanism differs fundamentally from antipsychotics:
- It is not a dopamine receptor blocker 4
- It acts on subcortical regions without cortical depression 4
- It has antihistaminic properties that may actually counteract some extrapyramidal effects
The real concern with TD is:
- Continuing or increasing dopamine-blocking antipsychotics 1
- The only definitive treatment for TD is discontinuing the causative medication 1
- VMAT-2 inhibitors are now first-line pharmaceutical treatment for moderate-to-severe TD 5
Bottom Line
You can safely use Vistaril in patients with tardive dyskinesia without concern for worsening their movement disorder. The limited research suggests it may even provide modest benefit, though this is not its primary indication. Focus your TD management on reducing or switching the causative antipsychotic and considering VMAT-2 inhibitors for moderate-to-severe cases.